Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrasTUCAN Study
2021-002561-18Phase 2Active
- Sponsor
- GEICAM
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib, trastuzumab and vinorelbine in breast cancer, sponsored by GEICAM. Primary endpoint: Objective response rate. Started Oct 2022; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-002561-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002561-18.